

UNCLASSIFIED

AD NUMBER
ADB284135
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 2002. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-01-1-0309

TITLE: The Influence of Estrogen on Breast Cancer Cell
Proliferation

PRINCIPAL INVESTIGATOR: Virginia A. Spencer
J. R. Davie, Ph.D.

CONTRACTING ORGANIZATION: University of Manitoba
Winnipeg, Manitoba, Canada R3E 0W3

REPORT DATE: July 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S.
Government agencies only (proprietary information, Jul 02). Other
requests for this document shall be referred to U.S. Army Medical
Research and Materiel Command, 504 Scott Street, Fort Detrick,
Maryland 21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

650 8111

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Annual Summary (15 Jun 01 - 14 Jun 02)	
4. TITLE AND SUBTITLE The Influence of Estrogen on Breast Cancer Cell Proliferation			5. FUNDING NUMBERS DAMD17-01-1-0309	
6. AUTHOR(S) Virginia A. Spencer J. R. Davie, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Manitoba Winnipeg, Manitoba, Canada R3E 0W3 Vspence@cc.umanitoba.ca			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
20021118 057				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) Estrogen affects both the cytoskeletal and chromatin structure of breast cancer cells. The treatment of breast cancer cells with 10 nM estradiol causes the estrogen receptor to recruit histone acetyltransferases to the promoter of the estrogen-responsive PS2 gene within 60 min, while exposure to estrogen for 72 h increases the levels of DNA-associated cytokeratins. To determine the effect of estrogen on regions downstream of estrogen-responsive promoters, quantitative PCR was performed on DNA isolated from chromatin immunoprecipitations using anti-acetylated H3 and H4 antibodies. Treatment with 10 nM estradiol induced a transient state of H3 and H4 acetylation along the PS2 promoter, exon 2, and exon 3, that was maximal after 60-120 min. After three hours, this hyperacetylation decreased to levels above those observed along the PS2 gene in untreated MCF-7 cells. To determine how estrogen influences DNA-associated cytokeratins, the levels of total, intermediate filament-assembled and DNA-associated cytokeratins were determined by Western Blotting and two dimension gel electrophoresis. The level of DNA-associated cytokeratins increased after 2 h of 10 nM estradiol treatment, while the levels of total and filament cytokeratins remained the same. This suggests that early estrogen exposure (i.e. 2 h) promotes interactions between cytokeratins and DNA.				
14. SUBJECT TERMS breast cancer, histone acetylation, transcription, estrogen, immunoprecipitation, cytoskeleton, cisplatin			15. NUMBER OF PAGES 14	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusions.....	7
References.....	8
Appendix.....	9

Introduction

Breast cancer proliferation is induced by estrogen, a hormone that induces the estrogen receptor to recruit histone acetyltransferases to the promoters of estrogen-responsive genes ¹. Upon recruitment, these enzymes acetylate the core histones H2A, H2B, H3 and H4, proteins that compose the nucleosome ². Acetylation of the core histones disrupts interactions between histones on adjacent chromatin fibers and causes chromatin to unravel; thereby allowing transcription factors access to their DNA-binding site ². The treatment of breast cancer cells with the anti-estrogen, ICI inhibits breast cancer development by causing the recruitment of histone deacetylases to the promoter of estrogen responsive genes ^{1,3}. These enzymes deacetylate core histones ². One of the goals of my research is to determine if estrogen and ICI affect the structure of chromatin along the promoter and exon regions of the PS2 gene, rather than just at the promoter alone.

The shape of a cell is governed by a dynamic tissue matrix system that links together three-dimensional skeletal networks from the nuclear matrix, cytoskeleton and extracellular matrix ^{4,5}. The NM binds to DNA regions along the chromatin fiber referred to as matrix attachment regions ⁶, organizing DNA into loop domains ². In addition to affecting the structure of chromatin, long term (72 h) exposure to estrogen increases the levels of cytoskeletal proteins such as cytokeratins ^{7,8}. Such proteins play an important role in the transduction of mechanical and chemical signals to the nucleus ⁹, and, therefore, are important in the development of breast cancer. In a previous study, exposure to estrogen for 72 h increased the levels of total and DNA-associated cytokeratins 8, 18 and 19 ⁷. Whether estrogen alters DNA organization by increasing the contacts between cytokeratins and DNA or by simply increasing the levels of cytokeratins associated with DNA remains to be determined. The second goal of my research is to determine if the treatment of breast cancer cells with estrogen causes immediate (within 1-2 h) changes in the levels of DNA-associated, intermediate filament-assembled and/or total cytokeratins.

Body

Task 1: To determine the effect of estrogen and anti-estrogen ligand on histone H3 and H4 acetylation within the gene promoter and coding region of the pS2 estrogen-responsive gene.

Method:

MCF-7 cells were grown in estrogen-deplete conditions for 72 h, and then treated with 10 nM estradiol for 0-3 h. The cells were then treated with 1% formaldehyde to cross-link any pre-existing protein-DNA complexes, lysed, and sonicated to fragment the DNA to an average size of 300-400 bp. The lysate was subjected to chromatin immunoprecipitation using antibodies to di-acetylated H3 and penta-acetylated H4 (Upstate Biotechnology, NY) ¹. The DNA associated with acetylated H3 and H4 was isolated and analyzed

by quantitative PCR using primers designed to amplify a 315 bp, 239 bp, and 196 bp region from the PS2 promoter, exon 2 and exon 3 regions, respectively.

Results:

Analysis of DNA immunoprecipitated with acetylated H3 and acetylated H4 antibodies by PCR revealed that the levels of acetylated H3 and H4 along the PS2 promoter, exon 2 and exon 3 regions began to increase as early as 30 min following 10 nM estradiol treatment (Figures 1 and 2 of Appendix). The acetylation of H3 was maximal along the three PS2 regions 60 min following estradiol treatment, and decreased when the cells were incubated for another 2 h to levels still greater than those observed in untreated cells (Figure 1 of Appendix). The level of acetylated H4 also appeared maximal along the PS2 promoter and exon 2 regions after 60 min exposure to 10 nM estradiol, and subsequently decreased along the promoter when the cells were incubated for another hour in the presence of estradiol. However, no further decrease in acetylated H4 was observed along the promoter in the third hour of estradiol treatment. As well, exon 2 displayed a constant level of H4 hyperacetylation following exposure to estradiol for 1 to 3 h. Exon 3 became maximally acetylated after 120 min exposure to estradiol, and then displayed a sharp decrease in acetylated H4 in the third hour of treatment.

Future Work:

Future studies will determine the effect of ICI on the acetylation of H3 and H4 along the PS2 gene. As well, I will determine if the transient histone acetylation we observed along the PS2 gene is dependent on the presence of transcription. To accomplish this, I will treat MCF-7 human breast cancer cells with different transcription inhibitors (e.g. α -amanitin, DRB) in the presence of estradiol and determine how these agents affect estrogen-induced histone acetylation along the PS2 gene.

Task 2: To determine if the effect of estradiol on the re-establishment of DNA-associated cytoskeletal intermediate filament and microfilament arrays occurs simultaneously or before down-regulation of p21 expression (i.e. before 8 hours exposure to 10 nM estradiol).

Method:

MCF-7 cells were grown in estrogen-deplete conditions for 72 h, and then treated with 10 nM estradiol for 0-2 h. The isolation of cytokeratins and actin cross-linked to DNA was performed as previously described⁷. In brief, MCF-7 cells were cross-linked with 1 mM cisplatin for 2 h, suspended in lysis buffer (5M urea, 2M NaCl, 2M guanidine hydrochloride), and the DNA-protein complexes isolated by hydroxyapatite chromatography. The DNA-cross-linked proteins were then analysed either by two-dimensional gel electrophoresis followed by silver staining or by Western Blotting using an antibody to

cytokeratins 8 and 18 (Biodesign International, ME) and β -actin (Sigma, ON). To determine if the levels of total or intermediate filament-assembled cytokeratins as well as DNA-associated cytokeratins changed in response to estradiol treatment, intermediate filament assembled cytokeratins were isolated as previously described ⁷ and analysed by two-dimensional gel electrophoresis. As well, total intermediate filament proteins were analysed from cell lysates.

Results:

Two dimensional gel electrophoresis of cisplatin DNA-cross-linked proteins isolated from MCF-7 cells treated with 10 nM estradiol for 0-2 h revealed an increase in the levels of DNA-associated cytokeratins after 1 h treatment with estradiol, followed by a further increase after 2 h of treatment (Figure 3A in Appendix). However, in a repeat study, no significant difference in DNA-associated cytokeratin levels could be observed by two dimensional gel electrophoresis over the 2 h estradiol treatment (Figure 3B in Appendix). Therefore, to improve the level of detection of cytokeratins within each sample, Western Blot analysis using an antibody to cytokeratins 8, 18 and 19 was performed on DNA cross-linked protein samples isolated from subsequent experiments (Figure 3C and D and Appendix). The results of these Western Blot analyses showed an increase in cytokeratins 8 and 18 approximately 2 h after treatment with 10 nM estradiol, while the level of cytokeratin 19 did not increase (Figure 3 in Appendix). Two-dimensional patterns of total and intermediate filament-assembled proteins did not display any significant changes in the levels of cytokeratins after exposure to estradiol for 2 h (Figure 4 in Appendix).

Future Work:

Experiments confirming the levels of total, intermediate filament-assembled, and DNA-associated cytokeratins after 2 h treatment with 10 nM estradiol need to be performed by Western blot analysis. The effect of estradiol on total and DNA-associated actin filaments also needs to be determined.

Key Research Accomplishments:

From Task 1:

- Treatment of MCF-7 cells with 10 nM estradiol induces a transient state of H3 and H4 acetylation along the PS2 promoter, exon 2, and exon 3 gene regions, that is maximal after 60-120 min exposure to estradiol. After three hours exposure to estradiol, this hyperacetylation decreases to levels above those observed along the PS2 gene in untreated MCF-7 cells.

From Task 2:

- Treatment of MCF-7 cells with 10 nM estradiol for 2 h causes an increase in the level of cytokeratins associated with DNA, while no increase is evident in intermediate filament-assembled or total cellular cytokeratins.

Reportable Outcomes:

Employment/research opportunities and post-doctoral research funding have not yet been presented since I have only recently begun looking for a post-doctoral position. However, the following are publications generated in the 2001-2002 award year:

1. Spencer, V. A. and Davie, J. R. (2002). Dynamic Histone Acetylation and its Role in Transcription. **Gene Ther. Mol. Biol.**, in press.
2. Spencer, V. A. and Davie, J. R. (2002). Isolation of Proteins Cross-Linked to DNA by Cisplatin. In *The Protein Protocols Handbook*, J. .M. Walker, ed. (Totowa: Humana Press), pp. 747-757.
3. Spencer, V. A. and Davie, J. R. (2002). Isolation of Proteins Cross-Linked to DNA by Formaldehyde. In *The Protein Protocols Handbook*, J. .M. Walker, ed. (Totowa: Humana Press), pp. 753-757.
4. K. L. Dunn, H. Zhao, V. A. Spencer, J. R. Davie. (2002). CTCF action at insulators. *Biochem. Cell Biol.* 80, 389.

Conclusions:

The presence of acetylated H3 and H4 along the PS2 gene in response to estradiol treatment suggests that H3 and H4 acetylation are involved in transcriptional elongation, as well as transcriptional initiation. In support of this, a 60-kilodalton subunit of the elongator/RNAPII holoenzyme (Elp3) is a histone acetyltransferase able to acetylate the core histones *in vitro*¹⁰. As well, the p300 histone acetyltransferase interacts specifically with the transcriptional initiation form of RNA polymerase II, while the PCAF acetyltransferase interacts with the transcriptional elongation form of RNA polymerase II¹¹.

Exposure to estrogen for 2 h increases the levels of cytokeratins associated with DNA, suggesting that exposure to estrogen promotes the interactions between cytokeratins and DNA. These interactions are most likely important for early stages of estrogen action (i.e. after 2 h exposure to estradiol). The cytokeratin 19 gene has an estrogen-response element, and the transcription of this gene is induced after 3 h exposure to estrogen¹². However, the accumulation of cytokeratin 19 occurs after 8 h exposure¹². Therefore, in addition to directly altering the interactions between DNA and cytokeratins, estrogen may still promote an increase in the association of cytokeratins with DNA simply by increasing the total cellular levels of cytokeratins. The cytoskeleton is linked to the nuclear matrix, the site of transcription². Therefore, changes in the components of the cytoskeleton structure most likely affect gene expression by altering the organization of the nuclear matrix and DNA. In support of this, treatment of fully differentiated mouse mammary epithelial cells with cytochalasin D, an actin microfilament inhibitor, causes cells to round up and inhibits total and casein protein synthesis in a concentration-dependent manner¹³. A loss of chromatin

organization correlates with malignancy¹⁴. Therefore, alterations in factors that directly or indirectly affect chromatin organization most likely affect breast cancer development and proliferation. Overall, the findings of our studies suggest that exposure to estradiol causes immediate changes in both the structure of estrogen-responsive genes, and the cytoskeletal component of the tissue matrix system. Future studies will confirm our current findings of the effect of estrogen on cytokeratin and actin levels, and determine if the estrogen-induced transient increase in histone acetylation along the PS2 gene is dependent on the process of transcription.

References

1. Chen, H., Lin, R. J., Xie, W., Wilpitz, D., and Evans, R. M. (1999) *Cell* **98**, 675-686
2. Davie, J. R. (1995) *Int.Rev.Cytol.* **162A**, 191-250
3. Torchia, J., Glass, C., and Rosenfeld, M. G. (1998) *Curr.Opin.Cell Biol.* **10**, 373-383
4. Penman, S. (1995) *Proc.Natl.Acad.Sci.U.S.A* **92**, 5251-5257
5. Maniotis, A. J., Chen, C. S., and Ingber, D. E. (1997) *Proc.Natl.Acad.Sci.U.S.A* **94**, 849-854
6. Bode, J., Schlake, T., Rios-Ramirez, M., Mielke, C., Stengert, M., Kay, V., and Klehr-Wirth, D. (1995) *Int.Rev.Cytol.* **162A**, 389-454
7. Spencer, V. A., Coutts, A. S., Samuel, S. K., Murphy, L. C., and Davie, J. R. (1998) *J.Biol.Chem.* **273**, 29093-29097
8. Coutts, A. S., Davie, J. R., Dotzlaw, H., and Murphy, L. C. (1996) *J.Cell Biochem.* **63**, 174-184
9. Ingber, D. E., Dike, L., Hansen, L., Karp, S., Liley, H., Maniotis, A., McNamee, H., Mooney, D., Plopper, G., Sims, J., and . (1994) *Int.Rev.Cytol.* **150**, 173-224
10. Wittschieben, B. O., Otero, G., de Bizemont, T., Fellows, J., Erdjument-Bromage, H., Ohba, R., Li, Y., Allis, C. D., Tempst, P., and Svejstrup, J. Q. (1999) *Mol.Cell* **4**, 123-128
11. Cho, H., Orphanides, G., Sun, X., Yang, X. J., Ogryzko, V., Lees, E., Nakatani, Y., and Reinberg, D. (1998) *Mol.Cell Biol.* **18**, 5355-5363
12. Choi, I., Gudas, L. J., and Katzenellenbogen, B. S. (2000) *Mol.Cell Endocrinol.* **164**, 225-237
13. Seely, K. A. and Aggeler, J. (1991) *J.Cell Physiol* **146**, 117-130
14. Komitowski, D. D., Hart, M. M., and Janson, C. P. (1993) *Cancer* **72**, 1239-1246

Appendix





Figure 1. Acetylation of H3 along the PS2 gene in response to treatment with 10 nM estradiol for 0-180 min. (A). Schematic diagram of PS2 gene. ERE represents the estrogen response element, the region of the PS2 promoter where the estrogen receptor binds (B). Fold enrichment of acetylated H3 along the promoter (pro), exon 2 and exon 3 region of the PS2 gene.




Figure 2. Fold enrichment of acetylated H4 along the PS2 promoter (pro), exon 2 and exon 3 gene regions in response to treatment with 10 nM estradiol for 0-180 min.




Figure 3. Treatment with estradiol increases the level of DNA-associated cytokeratins in MCF-7 human breast cancer cells. K8, K18, K19 and E2 represent cytokeratins 8, 18, 19, and estrogen, respectively. (A). Two-dimensional profile of silver-stained cisplatin DNA-cross-linked protein (20 ug) in MCF-7 cells treated with 10 nM estradiol for 0 - 120 min. (B). Repeat of (A) except on a different passage of MCF-7 cells. (C). Western Blot analysis of 10 ug of cisplatin DNA cross-linked proteins from MCF-7 cells treated with 10 nM estradiol for 0 - 24 h using an antibody to cytokeratins 8, 18 and 19. (D). Repeat of (C) except on a different passage of MCF-7 cells.




Figure 4. Estradiol does not alter the levels of assembled or total intermediate filaments in MCF-7 human breast cancer cells. MCF-7 cells were treated with 10 nM estradiol for 0 - 120 min and the total (20 ug) and intermediate filament-assembled (15 ug) cytokeatins were isolated, and analysed by two dimension gel electrophoresis followed by silver staining. IF, E2, K8, K18 and K19 represent intermediate filaments, estrogen, cytokeatins 8, cytokeatins 18 and cytokeatins 19, respectively.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MCMR-RMI-S (70-1y)

15 May 03

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB266022	ADB265793
ADB260153	ADB281613
ADB272842	ADB284934
ADB283918	ADB263442
ADB282576	ADB284977
ADB282300	ADB263437
ADB285053	ADB265310
ADB262444	ADB281573
ADB282296	ADB250216
ADB258969	ADB258699
ADB269117	ADB274387
ADB283887	ADB285530
ADB263560	
ADB262487	
ADB277417	
ADB285857	
ADB270847	
ADB283780	
ADB262079	
ADB279651	
ADB253401	
ADB264625	
ADB279639	
ADB263763	
ADB283958	
ADB262379	
ADB283894	
ADB283063	
ADB261795	
ADB263454	
ADB281633	
ADB283877	
ADB284034	
ADB283924	
ADB284320	
ADB284135	
ADB259954	
ADB258194	
ADB266157	
ADB279641	
ADB244802	
ADB257340	
ADB244688	
ADB283789	
ADB258856	
ADB270749	
ADB258933	